Senthil Radhakrishnan

Dr. Senthil Radhakrishnan

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2005 in Cancer Research
Verified
Journal Article
Closed access
PDF file
AGandrei gartel
andrei gartel
SRSenthil Radhakrishnan
Senthil Radhakrishnan
The cyclin-dependent kinase inhibitor p21WAF1/CIP1 is a major player in cell cycle control and it is mainly regulated at the transcriptional level. Whereas induction of p21 predominantly leads to cell cycle arrest, repression of p21 may have a variety of outcomes depending on the context. In this review, we concentrate on transcriptional repression of p21 by cellular and viral factors, and delve in detail into its possible biological implications and its role in cancer. It seems that the major mode of p21 transcriptional repression by negative regulators is the interference with positive transcription factors without direct binding to the p21 promoter. Specifically, the negative factors may either inhibit binding of positive regulators to the promoter or hinder their transcriptional activity. The ability of p21 to inhibit proliferation may contribute to its tumor suppressor function. Because of this, it is not surprising that a number of oncogenes repress p21 to promote cell growth and tumorigenesis. However, p21 is also an inhibitor of apoptosis and p21 repression may also have an anticancer effect. For example, c-Myc and chemical p21 inhibitors, which repress p21, sensitize tumor cells to apoptosis by anticancer drugs. Further identification of factors that repress p21 is likely to contribute to the better understanding of its role in cancer.

1 April 2010 in Molecular Cell
Verified
Journal Article
Closed access
SRSenthil Radhakrishnan
Senthil Radhakrishnan
CLCandy S. Lee
Candy S. Lee
PYPatrick Young
Patrick Young
ABAnne Beskow
Anne Beskow
JCJefferson Y. Chan
Jefferson Y. Chan
RDRaymond J. Deshaies
Raymond J. Deshaies

21 January 2014 in eLife
Verified
Journal Article
Open access
SRSenthil Radhakrishnan
Senthil Radhakrishnan
WBWillem Den Besten
Willem Den Besten
RDRaymond J Deshaies
Raymond J Deshaies
Proteasome inhibition elicits an evolutionarily conserved response wherein proteasome subunit mRNAs are upregulated, resulting in recovery (i.e., ‘bounce-back’) of proteasome activity. We previously demonstrated that the transcription factor Nrf1/NFE2L1 mediates this homeostatic response in mammalian cells. We show here that Nrf1 is initially translocated into the lumen of the ER, but is rapidly and efficiently retrotranslocated to the cytosolic side of the membrane in a manner that depends on p97/VCP. Normally, retrotranslocated Nrf1 is degraded promptly by the proteasome and active species do not accumulate. However, in cells with compromised proteasomes, retrotranslocated Nrf1 escapes degradation and is cleaved N-terminal to Leu-104 to yield a fragment that is no longer tethered to the ER membrane. Importantly, this cleavage event is essential for Nrf1-dependent activation of proteasome gene expression upon proteasome inhibition. Our data uncover an unexpected role for p97 in activation of a transcription factor by relocalizing it from the ER lumen to the cytosol.

25 October 2017 in ACS Central Science
Verified
Journal Article
Open access
FTFrederick M. Tomlin
Frederick M. Tomlin
UGUlla I. M. Gerling-Driessen
Ulla I. M. Gerling-Driessen
YLYi-Chang Liu
Yi-Chang Liu
RFRyan A. Flynn
Ryan A. Flynn
JVJanakiram R. Vangala
Janakiram R. Vangala
CBCarolyn Bertozzi
Carolyn Bertozzi
Proteasome inhibitors are used to treat blood cancers such as multiple myeloma (MM) and mantle cell lymphoma. The efficacy of these drugs is frequently undermined by acquired resistance. One mechanism of proteasome inhibitor resistance may involve the transcription factor Nuclear Factor, Erythroid 2 Like 1 (NFE2L1, also referred to as Nrf1), which responds to proteasome insufficiency or pharmacological inhibition by upregulating proteasome subunit gene expression. This “bounce-back” response is achieved through a unique mechanism. Nrf1 is constitutively translocated into the ER lumen, N-glycosylated, and then targeted for proteasomal degradation via the ER-associated degradation (ERAD) pathway. Proteasome inhibition leads to accumulation of cytosolic Nrf1, which is then processed to form the active transcription factor. Here we show that the cytosolic enzyme N-glycanase 1 (NGLY1, the human PNGase) is essential for Nrf1 activation in response to proteasome inhibition. Chemical or genetic disruption of NGLY1 activity results in the accumulation of misprocessed Nrf1 that is largely excluded from the nucleus. Under these conditions, Nrf1 is inactive in regulating proteasome subunit gene expression in response to proteasome inhibition. Through a small molecule screen, we identified a cell-active NGLY1 inhibitor that disrupts the processing and function of Nrf1. The compound potentiates the cytotoxicity of carfilzomib, a clinically used proteasome inhibitor, against MM and T cell-derived acute lymphoblastic leukemia (T-ALL) cell lines. Thus, NGLY1 inhibition prevents Nrf1 activation and represents a new therapeutic approach for cancers that depend on proteasome homeostasis.

1 October 2006 in Cancer Research
Verified
Journal Article
Closed access
SRSenthil Radhakrishnan
Senthil Radhakrishnan
UBUppoor G. Bhat
Uppoor G. Bhat
DHDouglas E. Hughes
Douglas E. Hughes
I-Ching WangI-Ching Wang
I-Ching Wang
RCRobert H. Costa
Robert H. Costa
AGAndrei L. Gartel
Andrei L. Gartel
The oncogenic transcription factor forkhead box M1 (FoxM1) is overexpressed in a number of different carcinomas, whereas its expression is turned off in terminally differentiated cells. For this reason, FoxM1 is an attractive target for therapeutic intervention in cancer treatment. As a first step toward realizing this goal, in this study, using a high-throughput, cell-based assay system, we screened for and isolated the antibiotic thiazole compound Siomycin A as an inhibitor of FoxM1. Interestingly, we observed that Siomycin A was able to down-regulate the transcriptional activity as well as the protein and mRNA abundance of FoxM1. Consequently, we found that the downstream target genes of FoxM1, such as Cdc25B, Survivin, and CENPB, were repressed. Also, we observed that consistent with earlier reports of FoxM1 inhibition, Siomycin A was able to reduce anchorage-independent growth of cells in soft agar. Furthermore, we found that Siomycin A was able to induce apoptosis selectively in transformed but not normal cells of the same origin. Taken together, our data suggest that FoxM1 inhibitor Siomycin A could represent a useful starting point for the development of anticancer therapeutics. (Cancer Res 2006; 66(19): 9731-5)

29 March 2004 in Oncogene
Verified
Journal Article
Closed access
PDF file
SRSenthil Radhakrishnan
Senthil Radhakrishnan
CFClaudine S Feliciano
Claudine S Feliciano
FNFeridoon Najmabadi
Feridoon Najmabadi
AHAndrea Haegebarth
Andrea Haegebarth
EKEugene S Kandel
Eugene S Kandel
AGAndrei L Gartel
Andrei L Gartel